Higher graft CD8 dose predicted better survival in patients undergoing reduced-intensity conditioned (RIC) allogenic hematopoietic stem-cell transplantation (alloHSCT) in adults with hematologic malignancies, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, researchers evaluated associations between graft T-cell doses and outcomes in 200 patients who underwent RIC alloHSCT with a peripheral blood stem-cell graft.
Results showed that higher CD8 cell doses were associated with a reduced risk for relapse (aHR = 0.43; P=0.009), improved relapse-free survival (aHR = 0.50; P=0.006), and improved overall survival (aHR = 0.57; P = 0.04). Researchers found no significant increase in graft-versus-host disease or nonrelapse mortality.
RELATED: Offspring of Older Fathers Face Higher Hematologic Cancer Risk
The study also demonstrated that donor age was inversely associated with graft CD8 dose, meaning younger donors were more likely to provide a higher CD8 cell dose graft.
Researchers were able to predict graft CD8 content by measuring the proportion of CD8 cells in a screening blood sample from donors.